Pubblicazioni

Autori:

Bellinato, Francesco; Gisondi, Paolo; Mason, Elena; Ricci, Paolo; Maurelli, Martina; Girolomoni, Giampiero

Titolo:

Real-Life Effectiveness of Adalimumab Biosimilars in Patients with Chronic Plaque Psoriasis

Anno:

2022

Tipologia prodotto:

Articolo in Rivista

Tipologia ANVUR:

Articolo su rivista

Lingua:

Inglese

Referee:

No

Nome rivista:

DERMATOLOGY AND THERAPY

ISSN Rivista:

2193-8210

N° Volume:

12

Numero o Fascicolo:

6

Intervallo pagine:

1303-1311

Parole chiave:

Adalimumab; Biosimilar; Drug survival; Early intervention; Psoriasis

Breve descrizione dei contenuti:

Introduction The real-life effectiveness of adalimumab biosimilars in patients with psoriasis has rarely been investigated. Objective To investigate drug survival of adalimumab biosimilars in patients with chronic plaque psoriasis and factors associated with its discontinuation. Methods We carried out a retrospective observational study including all consecutive patients with chronic plaque psoriasis who initiated adalimumab biosimilar MSB11022 (Idacio), ABP501 (Amgevita), or SB5 (Imraldi) between 1 January 2018 and 1 January 2021. The 1-year drug survival of adalimumab biosimilar and independent factors associated with its discontinuation were investigated. Cox regression models were fit to estimate adjusted hazard ratios (aHRs) with 95% confidence intervals (CIs) for the risk of adalimumab discontinuation. A propensity score matching (PSM) model was adopted as sensitivity analysis. Results The study involved a total of 410 patients with follow-up of 549.84 person-years, 271 (66.1%) men, a mean (SD) age of 51.8 (14.5) years, and a baseline PASI of 14.54 (5.02). Among adalimumab biosimilars, 250 (61%) patients received MSB11022, 98 (24%) received ABP501, and 62 (15%) received SB5. Drug survival of adalimumab biosimilars at 1 year was 81.5% in the overall study population. Obesity was associated with increased risk of adalimumab discontinuation (HR = 2.01; 95% CI 1.33-3.03), whereas psoriatic arthritis (aHR = 0.32; 95% CI 0.16-0.64) and receiving adalimumab as first systemic treatment (aHR = 0.44; 95% CI 0.27-0.70) were associated with lower risk. Conclusion The real-life effectiveness of adalimumab biosimilars in patients with psoriasis is consistent with that previously reported for the originator.

Id prodotto:

132343

Handle IRIS:

11562/1087010

ultima modifica:

18 maggio 2023

Citazione bibliografica:

Bellinato, Francesco; Gisondi, Paolo; Mason, Elena; Ricci, Paolo; Maurelli, Martina; Girolomoni, Giampiero, Real-Life Effectiveness of Adalimumab Biosimilars in Patients with Chronic Plaque Psoriasis «DERMATOLOGY AND THERAPY» , vol. 12 , n. 6 , 2022 , pp. 1303-1311

Consulta la scheda completa presente nel repository istituzionale della Ricerca di Ateneo